The fund, called 270 Life Sciences Private Capital Fund I, attracted strong support from investors including family offices, corporate partners, institutional allocators, and high net worth individuals. The fund will focus its investments on private biotechnology companies and will be agnostic about the stage, modality, geography, and therapeutic area of the investment.
Early investments will target biotechs in the cardiometabolic disease, immunology, oncology and genetic medicine spaces. The fund is led by Squinto and managing partner Gaurav Gupta.